CrossrefInfokarte
Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis
Allergologie select · 2021-01-01 · 5 (01) · 128-132
DOI: 10.5414/alx02196e ↗Abstract
Kein Abstract verfügbar.
EUVIMED